Thus, miR-7 ‘replacement therapy’ holds a promise as a potential strategy to reverse pan-TKI resistance in HCC patients by simultaneously targeting CAV1 and other oncogenic drivers. This evidence concerns the gene CAV1 and hepatocellular carcinoma.